
    
      This is a Phase 3, single-arm, multicenter open label extension (OLE) study designed to
      investigate the long-term safety and efficacy of 150 mg risankizumab in the treatment of
      moderate to severe chronic plaque psoriasis. Approximately 2200 participants who meet the
      entry criteria are planned to be enrolled in this study, rolling over from the preceding
      Phase 2/3 studies.
    
  